PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28042144-6	2017	Co-treatment with ARV-825 and JAK inhibitor ruxolitinib was synergistically lethal against established and PD CD34+ sAML cells.	ruxolitinib	44-55	CD34 molecule	Homo sapiens	110-114	
33747208-9	2021	Furthermore, zileuton and ruxolitinib exerted their anticancer effects by suppressing hematopoietic colony formation, inducing apoptosis and arresting the cell cycle of human CD34+ cells from patients with PV.	ruxolitinib	26-37	CD34 molecule	Homo sapiens	175-179	
34638347-6	2021	We also showed that proteasome gene expression is reduced by ruxolitinib in MF CD34+ cells and that additional targeting of proteasomal activity by carfilzomib enhances the inhibitory action of ruxolitinib in vitro.	ruxolitinib	61-72	CD34 molecule	Homo sapiens	79-83	
26115187-0	2016	Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.	ruxolitinib	103-114	CD34 molecule	Homo sapiens	40-44	
26227854-8	2015	Moreover, GLS inhibitor increased the growth inhibitory effect of Ruxolitinib in both JAK2(V617F)-mutant cell lines and peripheral blood CD34+ cells from MPN patients.	ruxolitinib	66-77	CD34 molecule	Homo sapiens	137-141	
25805962-13	2015	Janus kinase (JAK) inhibitor ruxolitinib (320 nM) had little or no effect on ATRA-induced differentiation, but eliminated the enhancing effect of G-CSF, as evidenced by the levels of CD11b and CD34 expression.	ruxolitinib	29-40	CD34 molecule	Homo sapiens	193-197